Table 1 Characteristics of the IVIG-treated group and the control group
From: High-dose of intravenous immunoglobulin modulates immune tolerance in premature infants
IVIG | Control | P value | |
|---|---|---|---|
Patients | 31 | 21 | |
Gender | |||
Male | 16 | 12 | 0.7626 |
Female | 15 | 9 | |
GA (w, median) | 33.5 (32.0–36.1) | 34.1 (30.1–36.3) | 0.1082 |
BW (g, median) | 2025 (1520–2670) | 2096(1540–2810) | 0.4923 |
Mode of delivery | 0.755 | ||
Vaginal | 7 | 5 | |
Cesarean | 24 | 16 | |
Preterm reasons | |||
PROM | 19 | 15 | 0.194 |
PIH | 9 | 4 | 0.064 |
PP | 3 | 2 | 1 |
NCPAP | 0.127 | ||
Yes | 16 | 9 | |
No | 15 | 12 | |
Apgar at 1 min | 7.43 | 7.85 | 0.1263 |
Apgar at 5 min | 8.71 | 9 | 0.2421 |
Hospital stay (d) | 15.2 | 12.67 | 0.0549 |
Prognosis | Cure | Cure | |